Gilead Sciences Inc. is in advanced talks to acquire Ouro Medicines, a closely held company testing novel antibody drugs against autoimmune diseases, according to a person familiar with the negotiations.
The person declined to comment on a potential price. The Financial Times, which reported the talks earlier today, said Foster City, California-based Gilead could pay as much as $2 billion under terms currently being discussed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.